Bicara Therapeutics (Nasdaq: BCAX) names new directors, forms launch panel
Rhea-AI Filing Summary
Bicara Therapeutics Inc. reported that Kiran Mazumdar‑Shaw will resign from its Board and Nominating and Corporate Governance Committee effective July 28, 2026; her decision was stated not to result from any disagreement with the company. The Board appointed Jeremy Bender as a Class I director through the 2028 annual meeting and Christy Oliger as a Class II director through the 2029 meeting, effective the same date, and increased the authorized Board size from nine to ten directors.
Both new directors are deemed independent under Nasdaq rules and, as non‑employee directors, will receive compensation that includes an initial stock option award of 38,950 shares of common stock and cash fees under Bicara’s director compensation policy. Bender joins the Audit Committee, while Oliger and Carolyn Ng join the Nominating and Corporate Governance Committee. The Board also created a Launch Readiness Committee, including Bender, Oliger and chair Kate Haviland, to provide strategic and operational guidance on Bicara’s commercialization strategy and launch readiness for its lead program, ficerafusp alfa.
Positive
- None.
Negative
- None.
Insights
Analyzing...
8-K Event Classification
3 items: 5.02, 7.01, 9.01
3 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Board size: nine to ten directors
Initial director option award: 38,950 shares
Day One acquisition value: $2.5 billion
+5 more
8 metrics
Board size
nine to ten directors
Authorized Board size increased effective July 28, 2026
Initial director option award
38,950 shares
Non-employee director initial non-qualified stock option award of common stock
Day One acquisition value
$2.5 billion
Acquisition of Day One Biopharmaceuticals by Servier in 2026
Genentech oncology revenue
exceeding $13 billion
U.S. revenue contributed by Genentech’s 15-product oncology portfolio led by Christy Oliger
Genentech oncology products
15 products
Size of oncology product portfolio managed by Christy Oliger
Oncology organization size
more than 800 people
Staff in Genentech’s oncology business unit led by Christy Oliger
Late-stage portfolio projects
greater than 300 projects
Size of late-stage development portfolio overseen by Christy Oliger as Global Head of Portfolio and Project Management
Bender industry experience
more than 20 years
Corporate strategy and operating experience in biotechnology attributed to Jeremy Bender
Key Terms
bifunctional therapies, tumor microenvironment, registration-enabling clinical study, head and neck squamous cell carcinoma, +1 more
5 terms
bifunctional therapies medical
"committed to bringing transformative bifunctional therapies to patients with solid tumors"
tumor microenvironment medical
"within the tumor microenvironment (TME) through the binding of EGFR"
The tumor microenvironment is the immediate area surrounding a cancer cell, made up of nearby cells, blood vessels, and support structures that influence how the cancer grows and spreads. It functions like a bustling neighborhood that can either help or hinder the tumor’s development. For investors, understanding changes in this environment can signal the effectiveness of treatments and potential shifts in a cancer-related market.
registration-enabling clinical study medical
"reach the important milestone of a registration-enabling clinical study"
head and neck squamous cell carcinoma medical
"developed in head and neck squamous cell carcinoma, where there remains"
A type of cancer that starts in the thin, flat cells that line the mouth, throat, voice box and upper airway; imagine the lining like roof shingles that, when damaged, can grow into a harmful lump. It matters to investors because its diagnosis, treatment options and regulatory approvals drive demand for drugs, tests and therapies—affecting clinical trial outcomes, market size, company valuations and the financial risk/reward of healthcare investments.
bifunctional epidermal growth factor receptor (EGFR) directed monoclonal antibody medical
"ficerafusp alfa, formerly BCA101, a bifunctional epidermal growth factor receptor (EGFR) directed monoclonal antibody"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What board changes did Bicara Therapeutics (BCAX) announce in July 2026?
Bicara announced that Kiran Mazumdar‑Shaw will resign from its Board effective July 28, 2026, and appointed Jeremy Bender and Christy Oliger as new independent directors, extending to the 2028 and 2029 annual meetings, and expanded the Board from nine to ten members.
Who are the new directors joining Bicara Therapeutics (BCAX)'s Board and what experience do they bring?
Jeremy Bender is the former CEO of Day One Biopharmaceuticals, where he led OJEMDA’s approval and a $2.5 billion acquisition by Servier. Christy Oliger is a former Genentech Senior Vice President who managed an oncology portfolio of 15 products with U.S. revenue exceeding $13 billion.
What is the Launch Readiness Committee created by Bicara Therapeutics (BCAX)?
Bicara formed a Launch Readiness Committee to provide strategic and operational guidance on commercialization strategy and launch readiness. The committee includes Jeremy Bender, Christy Oliger and chair Kate Haviland, and will advise the Board on strategic commercial considerations for ficerafusp alfa and other programs.
What compensation will the new Bicara Therapeutics (BCAX) directors receive?
As non‑employee directors, Jeremy Bender and Christy Oliger will receive compensation under Bicara’s director compensation policy, including an initial non‑qualified stock option award of 38,950 shares of common stock and cash compensation for Board and committee service as outlined in that policy.
Why did Kiran Mazumdar-Shaw resign from Bicara Therapeutics (BCAX)'s Board?
Kiran Mazumdar‑Shaw retired from Bicara’s Board effective July 28, 2026. The company stated that her decision to resign was not due to any disagreement with Bicara regarding its operations, policies or practices, and highlighted her significant founding and strategic contributions.
What is ficerafusp alfa, the lead program of Bicara Therapeutics (BCAX)?
Ficerafusp alfa is a bifunctional EGFR‑directed monoclonal antibody bound to a TGF‑β ligand trap. It is designed to block EGFR‑driven tumor survival and immunosuppressive TGF‑β signaling in the tumor microenvironment and is being developed for head and neck squamous cell carcinoma and other solid tumors.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________________________
FORM 8-K
___________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported): July 23, 2026
___________________________________
(Exact name of registrant as specified in its charter)
___________________________________
(State or other jurisdiction of incorporation or organization) | (Commission File Number) | (I.R.S. Employer Identification Number) | ||||||
(Address of principal executive offices and zip code) | ||||||||
( | ||||||||
(Registrant's telephone number, including area code) | ||||||||
___________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act: | ||||||||
Title of each class | Trading Symbol | Name of each exchange on which registered | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 12b-2 of the Exchange Act.
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
Compensatory Arrangements of Certain Officers.
Resignation of Kiran Mazumdar-Shaw
On July 23, 2026, Kiran Mazumdar-Shaw resigned from the Board of Directors (the “Board”) of Bicara Therapeutics Inc. (the “Company”) and her position on the Nominating and Corporate Governance Committee of the Board (the “Nominating and Corporate Governance Committee”), effective as of July 28, 2026. Ms. Mazumdar-Shaw’s decision to resign from the Board was not the result of any disagreement with the Company on any matter relating to the operations, policies or practices of the Company.
Appointment of Jeremy Bender, Ph.D. and Christy Oliger
On July 26, 2026, upon the recommendation of the Nominating and Corporate Governance Committee, the Board appointed (i) Jeremy Bender, Ph.D. to serve on the Board as a Class I director to hold office until the Company’s annual meeting of stockholders in 2028 or until his earlier death, resignation or removal, and (ii) Christy Oliger to serve on the Board as a Class II director to hold office until the Company’s annual meeting of stockholders in 2029 or until her earlier death, resignation or removal, with each appointment to be effective as of July 28, 2026 (the “Appointment Date”). The Board determined that each of Dr. Bender and Ms. Oliger is independent under the applicable listing standards of the Nasdaq Global Market. In connection with these appointments, the Board increased the authorized size of the Board from nine to ten directors, effective as of the Appointment Date.
As non-employee directors, Dr. Bender and Ms. Oliger will receive compensation, including an initial non-qualified stock option award of 38,950 shares of the Company’s common stock and cash compensation for their Board and committee service, in accordance with the Company’s Second Amended and Restated Non-Employee Director Compensation Policy, a copy of which the Company intends to file with the SEC as an exhibit to the Company’s Quarterly Report on Form 10-Q for the quarter ending September 30, 2026.
Dr. Bender and Ms. Oliger are not parties to any transaction with the Company that would require disclosure under Item 404(a) of Regulation S-K, and there are no arrangements or understandings between Dr. Bender and Ms. Oliger and any other persons pursuant to which they were selected as directors. In addition, Dr. Bender and Ms. Oliger have each entered into an indemnification agreement with the Company consistent with the form of indemnification agreement, a copy of which was previously filed as Exhibit 10.4 to the Company’s Registration Statement on Form S-1/A on September 6, 2024.
Board Committee Updates
Effective as of the Appointment Date, the Board appointed (i) Dr. Bender to serve as a member of the Audit Committee of the Board (the “Audit Committee”), replacing Carolyn Ng, Ph.D., (ii) Ms. Oliger and Dr. Ng to serve as a members of the Nominating and Corporate Governance Committee, replacing Ms. Mazumdar-Shaw and Jake Simson, Ph.D., and (iii) Dr. Bender, Ms. Oliger and Kate Haviland to serve as members of the newly formed Launch Readiness Committee of the Board (the “Launch Readiness Committee”), with Ms. Haviland as chair of the Launch Readiness Committee, each until their respective successors are elected and qualified, or until their earlier death, resignation or removal, or until otherwise determined by the Board.
The Launch Readiness Committee was formed as of the Appointment Date for the purpose of providing strategic and operational guidance to management of the Company in connection with the Company’s commercialization strategy and launch readiness and to advise the Board with respect to strategic commercial considerations.
The Board has determined that Dr. Bender meets the requirements for independence of audit committee members under the applicable listing standards of the Nasdaq Global Market and the Securities Exchange Act of 1934, as amended (the “Exchange Act”).
As a result of the changes described above, the members of the committees of the Board are as follows:
Audit Committee •Scott Robertson (Chair) •Michael Powell, Ph.D. •Jeremy Bender, Ph.D. Compensation Committee – no changes •Michael Powell, Ph.D. (Chair) •Christopher Bowden, M.D. •Kate Haviland | Nominating and Corporate Governance Committee •Michael Powell, Ph.D. (Chair) •Carolyn Ng, Ph.D. •Christy Oliger Launch Readiness Committee •Kate Haviland (Chair) •Jeremy Bender, Ph.D. •Christy Oliger | ||||
Dr. Powell continues to serve as Chair of the Board.
Item 7.01. Regulation FD Disclosure.
On July 28, 2026, the Company issued a press release titled “Bicara Therapeutics Announces Appointments of Jeremy Bender and Christy Oliger to Board of Directors.” A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information set forth under Item 7.01, including Exhibit 99.1, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01 - Financial Statements and Exhibits
(d) The following exhibits are being filed herewith:
Exhibit No. | Description | |||||||
99.1 | Press Release, dated July 28, 2026, furnished herewith. | |||||||
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | |||||||
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Bicara Therapeutics Inc. | |||||||||||
Date: July 28, 2026 | By: | /s/ Claire Mazumdar | |||||||||
Name: | Claire Mazumdar, Ph.D. | ||||||||||
Title: | Chief Executive Officer | ||||||||||
Bicara Therapeutics Announces Appointments of Jeremy Bender and Christy Oliger to Board of Directors
BOSTON, July 28, 2026 – Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced the appointments of Jeremy Bender, Ph.D., MBA and Christy Oliger to its Board of Directors. Dr. Bender, who most recently served as Chief Executive Officer at Day One Biopharmaceuticals through its acquisition by Servier in 2026, brings more than 20 years of corporate strategy and operating experience in biotechnology to Bicara. Ms. Oliger brings more than 30 years of commercial and operating experience in global biopharmaceutical organizations, having most recently served as Senior Vice President of the Oncology Business Unit at Genentech.
"We are delighted to welcome Jeremy and Christy to our Board of Directors at this pivotal time for Bicara. Together, they bring deep commercial, strategic, and operational expertise that will be invaluable as we continue our evolution from a clinical-stage organization to one focused on successfully delivering ficerafusp alfa to patients,” said Claire Mazumdar, Ph.D., MBA, Chief Executive Officer of Bicara Therapeutics. “Each of these distinguished professionals has an established track record of guiding innovative biopharmaceutical companies through critical stages of growth, including pipeline development, corporate strategy, and commercialization. Their perspectives will strengthen our Board as we advance our portfolio, execute on our long-term vision, and continue building Bicara into a mature biopharmaceutical organization.”
In addition, Kiran Mazumdar-Shaw has retired from Bicara’s Board of Directors.
"As one of our founding Board members, Kiran has been instrumental in shaping Bicara from its earliest days. Her impact extends beyond the initial seed capital that helped launch the company, but also the strategic guidance and steadfast support that has enabled Bicara to advance ficerafusp alfa into the clinic and reach the important milestone of a registration-enabling clinical study,” said Mike Powell, PhD, Chairman of Board of Bicara Therapeutics. “On behalf of the Board, management team, and Bicara employees, I want to thank Kiran for her vision, leadership, and indelible contributions to Bicara.”
About Jeremy Bender, Ph.D., MBA
Dr. Bender most recently served as Chief Executive Officer, President and a member of the Board of Directors of Day One Biopharmaceuticals, Inc. from September 2020 to April 2026, where he led the company through its evolution into a commercial-stage oncology company, including the approval and launch of OJEMDA® for pediatric low-grade glioma and the company's approximately $2.5 billion acquisition by Servier in 2026.
Prior to joining Day One, Dr. Bender was Vice President of Corporate Development at Gilead Sciences, Inc., a pharmaceutical company, from March 2018 to September 2020. Prior to that, he was Chief Operating Officer of Tizona Therapeutics, Inc. from July 2015 to March 2018 and Chief Business Officer
of Sutro Biopharma, a biotechnology company specializing in cancer and autoimmune therapeutics, from October 2012 to July 2015. Prior to joining Sutro Biopharma, Inc., he was Vice President of Corporate Development at Allos Therapeutics Inc., a biotechnology company focused on cancer treatments, from January 2006 to September 2012.
Dr. Bender began his career in the life sciences practice at Boston Consulting Group, a management consulting company. Dr. Bender also sits on the boards of Mereo BioPharma Group plc and Aura Biosciences, Inc. From October 2023 to June 2024, Dr. Bender also served as a director of Fusion Pharmaceuticals, Inc., a biopharmaceutical company. Dr. Bender holds a B.S. in Biological Sciences from Stanford University, a Ph.D. in Microbiology and Immunology from the University of Colorado, and an MBA from the MIT Sloan School of Management.
About Christy Oliger
Ms. Oliger is recognized for building industry leading capabilities and teams and was the Senior Vice President, Business Unit Head for Oncology and Genentech from 2017-2020, managing a portfolio of 15 products, contributing U.S. revenue exceeding $13 billion, delivering launches in lung cancer, breast cancer, chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL), melanoma and leading an organization of more than 800 people. Prior to this role, Ms. Oliger served as Senior Vice President and Business Unit Head, Neurology, Rare Disease, Infectious disease where she was responsible for building the teams and driving successful launches in multiple sclerosis (MS) (Ocrevus®), hemophilia (Hemlibra®) and spinal muscular atrophy (SMA) (Evrysdi®), together the most significant growth drivers in the U.S. business.
Prior to these roles, she spent three years as Global Head of Portfolio and Project Management where her team was responsible for the Late-Stage Portfolio Committee comprised of a late-stage development portfolio of greater than 300 projects across multiple therapeutic areas.
Christy began her career in life sciences at Schering Plough, a pharmaceutical company. In addition to Bicara, Christy also currently sits on the boards of Vera Therapeutics, Karyopharm Therapeutics, and Replimune Inc. She previously served as a director at Nuvalent Inc. prior to acquisition by GSK, Sierra Oncology prior to acquisition by GSK, Reata Pharmaceuticals prior to acquisition by Biogen, Rayze Bio prior to acquisition by BMS, and Lava Oncology prior to acquisition by Xoma Therapeutics. She holds a B.A. in Economics from University of California, Santa Barbara.
About Bicara Therapeutics
Bicara is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Bicara has built a platform designed to facilitate the development of bifunctional therapies that precisely target the tumor and deliver a tumor-modulating payload to the tumor site. This approach was deployed in the development of Bicara’s lead program ficerafusp alfa, formerly BCA101, a bifunctional epidermal growth factor receptor (EGFR) directed monoclonal antibody bound to a human transforming growth factor beta (TGF-β) ligand trap. By combining these two clinically validated targets, ficerafusp alfa has the potential to exert potent anti-tumor activity by simultaneously blocking both cancer cell-intrinsic EGFR survival and proliferation, as well as the immunosuppressive TGF-β signaling within the tumor microenvironment (TME). Ficerafusp alfa directs the TGF-β inhibitor into the immediate TME through the binding of EGFR on tumor cells, which Bicara believes will lead to deep and durable responses and an increase in overall survival, while reducing the potential adverse effects previously associated with systemic TGF-β inhibition. Ficerafusp
alfa is being developed in head and neck squamous cell carcinoma, where there remains a significant unmet need, as well as other solid tumor types. For more information, please visit www.bicara.com or follow us on LinkedIn and X.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may be identified by words such as “may,” “might,” “will,” “could,” “would,” “should,” “plan,” “anticipate,” “intend,” “believe,” “expect,” “estimate,” “seek,” “predict,” “future,” “project,” “potential,” “continue,” “target” and similar words or expressions, or the negative thereof, are intended to identify forward-looking statements, although not all contain identifying words. Any statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, express or implied statements regarding Bicara’s strategy, business plans and focus; the clinical development of ficerafusp alfa, including planned and ongoing clinical trials; the expected therapeutic potential and clinical benefits of ficerafusp alfa, including potential efficacy, depth, durability and tolerability; Bicara’s ability to scale and prepare for potential commercialization of ficerafusp alfa; the potential for U.S. regulatory approval and launch of ficerafusp alfa; and anticipated contributions of members of Bicara’s Board of Directors. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks and uncertainties that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks relating to Bicara’s research and development activities; Bicara’s ability to execute on its business plans and strategy, including obtaining the requisite regulatory approvals on the expected timeline, if at all; uncertainties relating to the clinical development of ficerafusp alfa; the Company’s dependence on third parties; risks related to the Company’s financial condition and need for additional funds in order to commercialize ficerafusp alfa, if approved; risks related to regulatory developments and approval processes of the U.S. Food and Drug Administration and comparable foreign regulatory authorities; risks related to establishing and maintaining Bicara’s intellectual property protections; and risks related to the competitive landscape for ficerafusp alfa; as well as other risks described in “Risk Factors,” in Bicara’s most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in Bicara’s subsequent filings with the U.S. Securities and Exchange Commission (SEC). In addition, any forward-looking statements represent Bicara’s views only as of today and should not be relied upon as representing its views as of any subsequent date. Bicara explicitly disclaims any obligation to update any forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.
Bicara intends to use its Investor Relations website as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor the Company’s Investor Relations website, in addition to following the Company’s press releases, SEC filings, public conference calls, presentations, and webcasts.
Contacts
Investors
Rachel Frank
IR@bicara.com
Rachel Frank
IR@bicara.com
Media
Tim Palmer
Tim Palmer
Tim.Palmer@bicara.com